Manchester
THIS series of contributions is concerned with the clinical experience at the Christie Hospital since 1955 with the 4 MV linear accelerator, in the treatment of certain malignant conditions. These are interim reports and in no case are five-year results available for study. In the past three to four years, however, certain treatment methods have evolved. In order to avoid repetition in the other papers some general remarks common to all can be made here.
Clinical work carried out before the results of the Relative Biological Efficiency (R.B.E.) experiments became available, had suggested that a higher dose of radiation at 4 MV levels was necessary to achieve a given effect, as compared with 250-300 kV. This was confirmed by the experimental results, which pointed to the figure of 85 as the R.B.E. for 4 MV radiation, compared to 100 for conventional therapy. To begin with, all megavoltage doses were not stepped up by this factor, and there was an initial period in some cases where tumour doses were lower than those now in use. Straight dosage comparison with previous cases treated by conventional radiation has been complicated for us by the introduction, not only of the rad in place of the rontgen, but also by the corrected depth dose tables for the 250-300 kV machines at the Christie Hospital. A number of random selection clinical trials, contrasting 250 or 500 kV with 4 MV radiation, are in progress at the moment, but the results are not yet ready for reporting. In the papers which follow comparison will be made between treatment methods and short-term results of small field megavoltage therapy in certain sites, with similar cases treated in the past by other radiation methods. Large field therapy will be considered, using seminoma as an example.
In the prophylactic treatment of seminoma following orchidectomy, certain principles have become accepted practice at the Christie Hospital.
(1) The irradiated volume includes the scrotum and the inguinal, iliac, and para-aortic lymphnode areas. Although recurrence locally in the scrotum occurs only rarely, it is considered advisable to treat the affected side. October 16-1 may be desirable to preserve the remaining testis, attempts at shielding it have two drawbacks-the likelihood that the shielding will only be partial, with subsequent genetic risks, and the danger of the shield slipping over to the affected side during treatment, and diminishing the dose delivered there. It is, therefore, our practice to irradiate the whole of the scrotum. In treating the inguinal nodes routinely, it is appreciated that metastases only occur there when the scrotum is involved, and their inclusion in the treated volume is, in part, due to the technique which has been employed.
(2) The volume to be treated should be irradiated in one block, without the need for matching field edges. This avoids the possibility of a low dose due to a gap between the fields, or an unduly high dose due to overlapping of the fields.
(3) The volume should be irradiated as homogeneously as possible.
The story of the evolution of the treatment technique is of some interest. Very briefly it started using 250 kV X-rays, with an opposed pair of 30 cm circular fields, anterior and posterior ( Fig. 1 ). This suffered from the usual limitations of low central dose and high skin dose. An improvement was the 3-field trunk bridge-an angled pair of anterior fields 30 x 22 5 cm opposed by a posterior 30 cm circular field (Fig. 2) . This improved the dose distribution, but the main volume was still not very homogeneously irradiated, with the maximum dose about the level of the skin of the abdominal wall. The lower limit of the treated volume was the perineum, and the level of the upper edge varied with the length of the patient. This method was superseded by the familiar fourfield trunk bridge ( Fig. 3 ), using 30 x 22-5 cm rectangular fields, which increased the volume homogeneously irradiated. In spite of the large volume treated, patients tolerated this treatment satisfactorily, without undue drop in the white blood count or troublesome radiation sickness. It was therefore decided that the fields should be lengthened to extend from the perineum to the dome of the diaphragm, and that beam flattening filters should be used to improve the depth dose at the top and bottom of the field. This was the method which was found to cause renal damage due to the inclusion of the kidneys in the high dose zone. Kunkler et al. (1952) demonstrated that a homogeneous dose of 2,000 rads, or over, in five weeks, to the whole of both kidneys may cause hypertension and renal failure and also showed that in the earlier techniques mentioned above, renal failure did not occur. This was because the upper third of the kidneys had received 1,500 rads or less in five weeks. It was therefore essential to protect the kidneys, and as lead shielding was not practical owing to the angled fields of the bridge, a return was made to the three-field method, omitting beam flattening filters. For additional safety, an Section of Radiology intravenous pyelogram (I.V.P.) was done and the fields were so arranged that the upper third of the kidneys received a dose not greater than that shown to be safe. The tumour dose was 2,500 rads, and this was achieved in about five weeks by a daily input which rose from 25 maximum of 75 rads per field. The gradually increasing input was considered to lessen the likelihood of radiation sickness and sudden leucopenia. My colleague, H. C. Warrington, decided to try an even daily input of about 125 rads per field, and the overall treatment time was reduced to four weeks, for the same dose, without apparent ill effect to the patient. About two years ago the linear accelerator became available for large field therapy, and seminomas were treated by it. Treatment reverted to a parallel opposed pair of fields, but with several important differences from the older techniques. No longer was it confined by applicators to circular or rectangular irradiated volumes. Fields of any desired size became available, and irregular shapes became possible by the interposition of lead blocks in the beam. With 4 MV radiation, depth dose is almost unaffected by the field size, and homogeneous radiation can be achieved in the treated volume, no matter what its shape (Fig. 4 ). This has the advantage that the kidneys can, if necessary, be completely shielded, whilst the para-aortic nodes lying between them receive adequate radiation.
The present prophylactic treatment of seminoma after orchidectomy is as follows: An I.V.P. is done, with a wire marker placed over a line drawn on the skin of the anterior abdominal wall, about the level of the iliac crests (Fig. 5) . A Perspex ruler, on which the centimetre divisions are enlarged to the same magnification as the radiograph, is used for measuring the size and position of the kidneys in relation to the marker wire. From these measurements the position of the medial edges and lower poles of the kidneys is transferred to the patient's skin, and during treatment the kidney areas are completely shielded. The upper margin of the anterior field is placed at the level of the xiphisternum, allowing generous clearance of the upper para-aortic nodes. The lower edge is at the perineum. In general the scrotum can be pushed upward, thus reducing the field length (Fig. 6) . The width treated is less than that with the bridge technique, but includes the iliac nodes and the greater part of the inguinal node area. A careful note is made of the position of the upper edge of the field, in case it is later necessary to irradiate the chest. The post-irradiation skin changes are not sufficiently obvious later to be an adequate guide to the position of the field edges, and recently we have been experimenting with tattooing with indian ink at the important points, to give an indelible mark. A replica of the anterior field is marked on the back of the patient. The usual size of the irradiated area is about 800-900 sq. cm, achieved with an F.S.D. of 130-150 cm. The tumour dose is 3,000 rads in four weeks, treating five days per week, and anterior and posterior fields are treated on alternate days. Bi-weekly blood counts are done, and there appears to be less of a drop in the white cells than with 250 kV. A comparison of twenty patients treated by 250 kV with a similar number at 4 MV, shows, however, an almost identical drop in the count. Radiation sickness and bowel reaction do not appear to differ significantly between the two techniques, but in general the patients treated by 4 MV seem to have an easier time. There is still difficulty in shielding adequately the remaining testis, and this is only attempted when the patient demands it. He is advised that no guarantee can be given as to the completeness of the shielding.
Where metastatic disease is present in the abdomen when the patient is first seen, shielding of the kidneys may not be practicable, particularly when a para-aortic mass overlies one or both. In such cases the whole volume, including the kidneys, is irradiated to 2,000 rads in about three weeks, by which time the metastatic mass has generally resolved enough to allow some shielding of kidney tissue, and with this in position treatment is continued to 3,000 rads in four weeks. If shielding is not possible owing to the presence of disease, the risk of kidney damage is accepted and treatment continued to full dosage.
Patients presenting with lung metastases, but without abdominal metastases, are treated by an opposed pair of fields to the chest, and lungs, mediastinum and supraclavicular fosse are included in the treated volume, the dose being 2,500 rads in four weeks. Again careful note is made of the position of the lower end of the field, to facilitate abdominal irradiation later, if called for.
For patients with both abdominal and lung metastases when first seen, a technique known as the "moving strip", which irradiated the whole of the trunk, was used many years ago. With conventional radiation the maximum dose to each strip was about 1,400 rads in eight days. Blood tolerance was a problem, results were poor, and the method fell into disuse. It was reintroduced about three years ago, using the accelerator, and it was found possible to give the abdominal strips 2,500 rads, and the lungs 2,250 rads, in eight days, with an overall treatment time of about two and a half to three months.
Of 12 patients with abdominal and lung metastases none survived for a reasonable length of time considering the very prolonged treatment. The one long-term survivor had an orchidectomy for a seminoma and presented with an upper abdominal mass and a large left supraclavicular node, which were accepted clinically as metastases. Both the masses resolved as a sensitive tumour would be expected to, and the patient remains free of disease at two and a half years. The primary was histologically proved, but it now seems a great pity that the supraclavicular node was not also biopsied. Apart from this one patient it appears that palliation can equally well, or even better, be provided by some simpler and less time-consuming treatment, although with seminoma it is probably always right to be hopeful of permanent regression, even with advanced disease. For the present, the moving strip has again been discarded.
To sum up, 4 MV radiation has simplified the technique of treating the abdomen and the chest in seminoma. Not only has it enabled a homogeneous dose to be given throughout the treated volume, but the use of irregularly shaped fields has been possible without loss of homogeneity. It also appears that the patient tolerates the treatment of large volumes by megavoltage radiation rather better than by the methods previously available. REFERENCE KUNKLER, P. B., FARR, R. F., and LUXTON, R. W.
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